Firefly Neuroscience (AIFF) Cash & Equivalents (2010 - 2026)

Firefly Neuroscience's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 67.24% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 67.24% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, up 51.77% from the prior year.
• Cash & Equivalents advanced to $3.1 million in Q1 2026 per AIFF's latest filing, from $2.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.5 million in Q1 2025 and bottomed at $58000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $1.6 million (2022), against an average of $2.3 million.
• Across the five-year window, Cash & Equivalents tumbled 98.82% in 2022 and soared 3594.83% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $58000.0 in 2022, then surged by 3594.83% to $2.1 million in 2023, then fell by 15.54% to $1.8 million in 2024, then soared by 51.77% to $2.7 million in 2025, then grew by 13.83% to $3.1 million in 2026.
• Per Business Quant, the three latest AIFF Cash & Equivalents figures stand at $3.1 million (Q1 2026), $2.7 million (Q4 2025), and $4.3 million (Q3 2025).